Kirsten A Nyrop1,2, Allison M Deal2, Kathryn E Reeder-Hayes1,2, Shlomit S Shachar3, Bryce B Reeve4, Ethan Basch1,2, Seul Ki Choi5, Jordan T Lee6, William A Wood1,2, Carey K Anders7, Lisa A Carey1,2, Elizabeth C Dees1,2, Trevor A Jolly1,2, Gretchen G Kimmick7, Meghan S Karuturi8, Raquel E Reinbolt9, JoEllen C Speca1, Hyman B Muss1,2. 1. Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, North Carolina. 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 3. Rambam Health Campus, Haifa, Israel. 4. Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina. 5. Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina. 6. Department of Exercise and Sport Science, University of North Carolina, Chapel Hill, North Carolina. 7. Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 8. Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas. 9. Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Abstract
BACKGROUND: In the current study, the authors investigated the incidence of moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) for chemotherapy regimens commonly used in current clinical practice for the treatment of patients with early breast cancer. Patient-reported and clinician-assessed CIPN severity scores were compared, and risk factors for CIPN severity were identified. METHODS: Patients completed a Patient-Reported Symptom Monitoring form and oncologists completed a Common Terminology Criteria for Adverse Events form. CIPN reports were collected prospectively during regularly scheduled infusion visits throughout the duration of chemotherapy. RESULTS: The sample included 184 women with a mean age of 55 years; approximately 73% were white. The 4 chemotherapy regimens used were doxorubicin and cyclophosphamide plus paclitaxel (60 patients); docetaxel and cyclophosphamide (50 patients); docetaxel, carboplatin, and anti-human epidermal growth factor receptor 2 (HER2) (24 patients); and doxorubicin and cyclophosphamide plus paclitaxel and carboplatin (18 patients). All patients treated with doxorubicin and cyclophosphamide plus paclitaxel and doxorubicin and cyclophosphamide plus paclitaxel and carboplatin received paclitaxel; all patients treated with docetaxel and cyclophosphamide and docetaxel, carboplatin, and anti-HER2 received docetaxel. The chemotherapy dose was reduced in 52 patients (28%); in 15 patients (29%), this reduction was due to CIPN. Chemotherapy was discontinued in 26 patients (14%), 8 because of CIPN. Agreement between patient-reported and clinician-assessed CIPN severity scores was minimal (weighted Cohen kappa, P = .34). Patient-reported moderate to severe CIPN was higher for paclitaxel (50%) compared with docetaxel (17.7%) (P < .001). Pretreatment arthritis and/or rheumatism (relative risk [RR], 1.58; 95% CI, 1.06-2.35 [P = .023]) and regimens containing paclitaxel (RR, 2.88; 95% CI, 1.72-4.83 [P < .0001]) were associated with higher CIPN severity. Being married (RR, 0.57; 95% CI, 0.37-0.887 [P = .01]) was found to be associated with lower CIPN severity. CONCLUSIONS: The discrepancy between patient-reported and clinician-assessed CIPN underscores the need for both patient and clinician perspectives regarding this common, dose-limiting, and potentially disabling side effect of chemotherapy.
BACKGROUND: In the current study, the authors investigated the incidence of moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) for chemotherapy regimens commonly used in current clinical practice for the treatment of patients with early breast cancer. Patient-reported and clinician-assessed CIPN severity scores were compared, and risk factors for CIPN severity were identified. METHODS:Patients completed a Patient-Reported Symptom Monitoring form and oncologists completed a Common Terminology Criteria for Adverse Events form. CIPN reports were collected prospectively during regularly scheduled infusion visits throughout the duration of chemotherapy. RESULTS: The sample included 184 women with a mean age of 55 years; approximately 73% were white. The 4 chemotherapy regimens used were doxorubicin and cyclophosphamide plus paclitaxel (60 patients); docetaxel and cyclophosphamide (50 patients); docetaxel, carboplatin, and anti-human epidermal growth factor receptor 2 (HER2) (24 patients); and doxorubicin and cyclophosphamide plus paclitaxel and carboplatin (18 patients). All patients treated with doxorubicin and cyclophosphamide plus paclitaxel and doxorubicin and cyclophosphamide plus paclitaxel and carboplatin received paclitaxel; all patients treated with docetaxel and cyclophosphamide and docetaxel, carboplatin, and anti-HER2 received docetaxel. The chemotherapy dose was reduced in 52 patients (28%); in 15 patients (29%), this reduction was due to CIPN. Chemotherapy was discontinued in 26 patients (14%), 8 because of CIPN. Agreement between patient-reported and clinician-assessed CIPN severity scores was minimal (weighted Cohen kappa, P = .34). Patient-reported moderate to severe CIPN was higher for paclitaxel (50%) compared with docetaxel (17.7%) (P < .001). Pretreatment arthritis and/or rheumatism (relative risk [RR], 1.58; 95% CI, 1.06-2.35 [P = .023]) and regimens containing paclitaxel (RR, 2.88; 95% CI, 1.72-4.83 [P < .0001]) were associated with higher CIPN severity. Being married (RR, 0.57; 95% CI, 0.37-0.887 [P = .01]) was found to be associated with lower CIPN severity. CONCLUSIONS: The discrepancy between patient-reported and clinician-assessed CIPN underscores the need for both patient and clinician perspectives regarding this common, dose-limiting, and potentially disabling side effect of chemotherapy.
Authors: Katherina C Chua; Chenling Xiong; Carol Ho; Taisei Mushiroda; Chen Jiang; Flora Mulkey; Dongbing Lai; Bryan P Schneider; Sara R Rashkin; John S Witte; Paula N Friedman; Mark J Ratain; Howard L McLeod; Hope S Rugo; Lawrence N Shulman; Michiaki Kubo; Kouros Owzar; Deanna L Kroetz Journal: Clin Pharmacol Ther Date: 2020-08-02 Impact factor: 6.875
Authors: Kirsten A Nyrop; Allison M Deal; Bryce B Reeve; Ethan Basch; Yi Tang Chen; Ji Hye Park; Shlomit S Shachar; Lisa A Carey; Katherine E Reeder-Hayes; Elizabeth C Dees; Trevor A Jolly; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Jordan T Lee; William A Wood; Hyman B Muss Journal: Cancer Date: 2020-04-21 Impact factor: 6.860
Authors: Jessica N Mezzanotte; Michael Grimm; Namrata V Shinde; Timiya Nolan; Lise Worthen-Chaudhari; Nicole O Williams; Maryam B Lustberg Journal: Curr Treat Options Oncol Date: 2022-02-15
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Henry Schulz Journal: Oncol Res Treat Date: 2021-10-13 Impact factor: 2.825
Authors: Ciao-Sin Chen; Ellen M Lavoie Smith; Kathleen A Stringer; N Lynn Henry; Daniel L Hertz Journal: Breast Cancer Res Treat Date: 2022-06-28 Impact factor: 4.624
Authors: Julie A Meade; Alison N Fowlkes; Mackinsey J Wood; Mary Claire Kurtz; Madeline M May; Wisam B Toma; Urszula O Warncke; Jared Mann; Mohammed Mustafa; Aron H Lichtman; M Imad Damaj Journal: Behav Pharmacol Date: 2021-08-01 Impact factor: 2.277
Authors: Zev M Nakamura; Allison M Deal; Kirsten A Nyrop; Yi Tang Chen; Laura J Quillen; Tucker Brenizer; Hyman B Muss Journal: Oncologist Date: 2020-10-02 Impact factor: 5.837